23 results about "Psychogenic disease" patented technology

This specification discloses a method for administering dexmedetomidine or a pharmaceutically acceptable salt thereof to human subjects. The disclosed method is particularly suitable for the treatment of agitation associated with neurodegenerative diseases and / or neuropsychiatric disorders or disorders (e.g., Alzheimer's disease).

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

Provided herein, inter alia, are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of Exosc9 The application discloses application of a gene mutation animal in construction of an anxiety model and in screening of an anti-anxiety drug. Exosc9 The gene mutation animal is a known model, but the application finds that the animal shows behavior phenotypes related to anxiety through systematic behavior experiments, including a decrease in central zone activity in an open field experiment, a decrease in open arm staying time in a high cross maze experiment, and a decrease in exploration behavior. Through behavior observation and quantitative analysis of the animal, the application can be used to study behavior characteristics of anxiety, compare phenotype differences of animals of different genotypes, genders and ages, and analyze influences of genetic and environmental factors on anxiety behavior. The application also constructs a method for screening of an anti-anxiety candidate drug and evaluation of drug efficacy based on the model, which can greatly shorten an early screening period of drug research and development, and has a wide application prospect in the field of neuropsychiatric disease research and drug research and development.

The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The application is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.

N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a tertiary alcohol-containing group substituted on the biarylmethylene are positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChRM1). The compounds and pharmaceutical compositions may be used in treating neurological disorders, psychiatric disorders, or a combination thereof.

This invention relates to compounds that are agonists of the muscarinic M1 and / or M4 receptors useful in the treatment of diseases mediated by the muscarinic M1 and / or M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic applications of the compounds. Specifically, the present disclosure is related to compounds that are useful in treating pain, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric and neurodegenerative diseases.

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.

Methods for increasing reelin (RELN) levels in the brain of a subject in need thereof, as well as compositions for use in such methods, are provided. In addition, methods and compositions are described herein which may be used in the treatment of neuropsychiatric or neurodegenerative disorders, such as schizophrenia and Alzheimer's disease (AD). Compositions described herein may comprise whey protein isolate and / or whey protein concentrate, a source of the glutathione precursor cysteine. The provided methods and compositions are not limited to increasing RELN levels, and may be used to correct a number of other neurological disregulations or abnormalities occurring in a subject in need thereof.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present application provides a combination product for the treatment and / or prevention of psychiatric and / or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and / or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and / or removes the hallucinogenic and / or psychedelic side effects caused by the first compound.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of Exosc9 The application discloses application of a gene mutation animal in construction of an anxiety model and in screening of an anti-anxiety drug. Exosc9 The gene mutation animal is a known model, but the application finds that the animal shows behavior phenotypes related to anxiety through systematic behavior experiments, including a decrease in central zone activity in an open field experiment, a decrease in open arm staying time in a high cross maze experiment, and a decrease in exploration behavior. Through behavior observation and quantitative analysis of the animal, the application can be used to study behavior characteristics of anxiety, compare phenotype differences of animals of different genotypes, genders and ages, and analyze influences of genetic and environmental factors on anxiety behavior. The application also constructs a method for screening of an anti-anxiety candidate drug and evaluation of drug efficacy based on the model, which can greatly shorten an early screening period of drug research and development, and has a wide application prospect in the field of neuropsychiatric disease research and drug research and development.

The present invention relates to a composition for preventing, alleviating, or treating autism spectrum disorders or related developmental disorders, the composition comprising Tebipenem pivoxil or a pharmaceutically acceptable salt thereof.

Provided in the present invention is a novel use of Pynegabine as represented by formula (I) in the preparation of drugs for treating or preventing psychiatric disorders such as depression and schizophrenia. The present invention shows that Pynegabine can exhibit a significant antidepressant effect in an acute forced swimming mouse model and a chronic social defeat stress mouse model; additionally, Pynegabine also has a significant alleviation effect on both positive and negative symptoms in an MK-801-induced mouse model of schizophrenia. The present invention shows good development and application prospects.

The present invention provides compositions, systems, and methods for treating or preventing brain disorder with compositions comprising a prebiotic (e.g., green banana flour) and one or both of Lactobacillus reuteri, and Lactobacillus plantarum. In certain embodiments, the brain disorder is selected from neuroinflammation, a neurological disorder, a neuropsychiatric disorder, and a behavioral disorder. In some embodiments, the prebiotic, Lactobacillus reuteri, and Lactobacillus plantarum are provided as a powder inside an ingestible capsule.

The present invention relates to cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]-decan-2-one derivatives, their preparation and use in medicine, in particular, but not limited to, use in various neurological disorders including pain, neurodegenerative diseases, neuroinflammatory diseases, neuropsychiatric disorders and substance abuse / dependence.